Your browser doesn't support javascript.
loading
A Novel Ornithine Aminotransferase Splice Site Mutation Causes Vitamin B6-Responsive Gyrate Atrophy.
Molaei Ramshe, Samira; Zardadi, Safoura; Alehabib, Elham; Nourinia, Ramin; Jamshidi, Javad; Soosanabadi, Mohsen; Darvish, Hossein.
Afiliação
  • Molaei Ramshe S; Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Zardadi S; Department of Biology, School of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.
  • Alehabib E; Student Research Committee, Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Nourinia R; Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Jamshidi J; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
  • Soosanabadi M; Neuroscience Research Australia, Randwick, Sydney, NSW, Australia.
  • Darvish H; Department of Medical Genetics, Semnan University of Medical Sciences, Semnan, Iran.
J Ophthalmic Vis Res ; 19(1): 118-132, 2024.
Article em En | MEDLINE | ID: mdl-38638626
ABSTRACT

Purpose:

Gyrate atrophy of the choroid and retina (GACR) is a rare congenital disorder and mutations in the ornithine aminotransferase (OAT) gene has been specified as the underlying cause. Patients show a high level of ornithine in body fluids which may be controlled by low protein diets. Pyridoxine (vitamin B6) supplementation may also be effective, however, most patients appear to be nonresponsive to this modality of treatment. Case Report Here, we report a characterized case of a vitamin B6-responsive GACR who had a splicing mutation in the OAT gene. The GACR diagnosis was confirmed through the clinical features, imaging, biochemical findings, and whole-exome sequencing (WES) results. WES data revealed the splicing mutation in intron 4 of the OAT gene (NM_001322967 c.425-1G>A).

Conclusion:

Our knowledge about the diagnosis and treatment of GACR can be improved by identifying novel mutations in the OAT gene and accurate follow-up of the patients to determine how they respond to treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article